Zusammenfassung
HINTERGRUND: Die Pathogenese von zystischen Schilddrüsenknoten ist nicht vollkommen geklärt. Ausgehend von der Annahme, dass der endotheliale Gefäßwachstumsfaktor (VEGF) eine wichtige Rolle in der Entstehung von Zystenflüssigkeit in Schilddrüsenzysten spielt, haben wir die VEGF-Konzentration in dieser Flüssigkeit untersucht. DESIGN: Zystenflüssigkeit aus zystischen Schilddrüsenknoten unterschiedlichen Ursprungs wurde in 24 Patienten (Alter: 31–84 Jahre) mittels ultraschallgezielter Feinnadelaspiration gewonnen. METHODE: Schilddrüsenvolumen und Zystenvolumen wurden mittels hochauflösendem Ultraschall gemessen. VEGF-Konzentrationen in der Zystenflüssigkeit wurden mit Hilfe eines Festphasen Enzym Verbindungs-Immunosorbent-Tests (ELISA) ermittelt. ERGEBNISSE: Unterschiedlich hohe VEGF-Konzentrationen konnten in den Zystenflüssigkeiten der verschiedenen zystischen Schilddrüsenknoten aufgezeigt werden. Die VEGF-Konzentration in der Zystenflüssigkeit von Patienten mit adenomatösen Schilddrüsenknoten war signifikant höher (p < 0,05) als die Konzentration von VEGF in der Zystenflüssigkeit von Schilddrüsenknoten mit zystischer Degeneration. Die höchsten VEGF-Konzentrationen wurden in blutigen Zystenflüssigkeiten ermittelt. Diese Konzentrationen waren signifikant höher als die VEGF-Konzentrationen in den übrigen Zystenflüssigkeiten (p < 0,05). Interessanterweise fand sich eine signifikante Korrelation (p < 0,01) zwischen den Schilddrüsenvolumen und den VEGF-Konzentrationen in den Zystenflüssigkeiten, während keine signifikante Beziehung (p = 0,20) zwischen den Zystenvolumen und den VEGF-Konzentrationen gefunden werden konnte. ZUSAMMENFASSUNG: Unsere Ergebnisse lassen vermuten, dass der endotheliale Gefäßwachstumsfaktor (VEGF) eine wichtige Rolle in der Entstehung von Zystenflüssigkeit in Schilddrüsenzysten spielt.
Summary
BACKGROUND: The pathogenesis of cystic thyroid nodules is incompletely understood. Based on the assumption that vascular endothelial growth factor (VEGF) may play an important role in the pathogenesis of thyroid cyst fluid, we investigated the VEGF concentration in cyst fluids of thyroid lesions. DESIGN: Cyst fluids from 24 patients (age 31–84 years) were obtained using ultrasound-guided fine-needle aspiration. The patients' cystic thyroid nodules were of different origins. METHODS: Thyroid and cyst volumes were determined using high-resolution ultrasonography. VEGF concentrations were determined using a solid-phase enzyme-linked immunosorbent assay (ELISA). RESULTS: Differing elevated VEGF concentrations were demonstrated in cyst fluids of thyroid nodules of varied origins. The VEGF concentration in cyst fluid of patients with adenomatous goiter was significantly higher (P < 0.05) than that in thyroid nodules with cystic degeneration. The highest level of VEGF was found in bloody cyst fluid when compared with levels in other cyst fluids (P < 0.05). Interestingly, there was significant correlation (P < 0.01) between thyroid volume and VEGF concentration in cyst fluid, but no significant correlation (P = 0.20) between cyst volume and VEGF concentration. CONCLUSION: Significantly increased VEGF concentrations were found in bloody cyst fluid and in cyst fluid of thyroid adenomatous goiter, compared with VEGF concentrations in degenerative thyroid cysts. Our results suggest that VEGF may play an important role in the pathogenesis of thyroid cyst fluid.
References
Castro M, Gharib H (2005) Continuing controversies in the management of thyroid nodules. Annals of Internal Medicine 142: 926–931
Salabe GB (2001) Pathogenesis of thyroid nodules: histological classification? Biomed Pharmacotherapy 55: 39–53
Sato K, Miyakawa M, Onoda N, Demura H, Yamashita T, Miura M, et al (1997) Increased concentration of vascular endothelial growth/vascular permeability factor in cyst fluid of enlarging and recurrent thyroid nodules. J Clin Endocrinol Metabol 82: 1968–1973
Ferrara N (2004) Vascular endothelial growth factor: basic science and clinical progress. Endocrine Review 25: 581–611
Senger DR, Connolly DT, Van De Water L, Feder J, Dvorak HF (1990) Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. Cancer Research 50: 1774–1778
Yeo TK, Senger DR, Dvorak HK, Freter L, Yeo KT (1991) Glycosylation is essential for efficient secretion but not for permeability enhancing activity of vascular permeability factor (vascular endothelial growth factor). Biochem Biophys Res Commun 179: 1568–1575
Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N (1989) Vascular endothelial factor is a secreted angiogenic mitogen. Science 246: 1306–1309
Conn G, Soderman DD, Schaeffer MT, Wile M (1990) Purification of a glycoprotein vascular endothelial cell mitogen from a rat glioma-derived cell line. Proc Natl Acad Sci USA 87: 1323–1327
Weindel K, Marme D, Weich HA (1992) AIDS-associated Kaposi's sarcoma cells in culture express vascular endothelial growth factor. Biochem Biophys Res Commun 183: 1167–1174
Berse B, Brown LF, Van de Water L, Dvorak HF, Senger DR (1992) Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. Mol Biol Cell 3: 211–220
Monacci WT, Merrill MJ, Oldfield EH (1993) Expressionof vascular permeability factor/vascular endothelial growth factor in normal rat tissues. Am J Physiology 264: C995–C1002
Sato K, Yamazaki K, Shizume K, Kanaji Y, Obara T, Ohsumi K, et al (1995) Stimulation of thyroid-stimulating hormone and Graves immunoglobulin G of vascular endothelial growth factor mRNA expression in human thyroid follicles in vitro and flt mRNA expression in the rat thyroid in vivo. J Clin Invest 96: 1295–1302
Fava RA, Olsen NJ, Spencer-Green G (1994) Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue. J Exp Med 180: 341–346
Gutekunst R, Smolarek H, Hasenpusch U, Stubbe P, Friedrich Wood WG, et al (1986) Goitre epidemiology: thyroid volume iodine excretion, thyroglobulin and thyrotropin in Germany and Sweden. Acta Endocrinol (Copenh) 112: 494–501
Hegedüs L, Perrild H, Poulsen RL, Andersen JR, Hgolm B, Schnor P, et al (1983) The determination of thyroid volume by ultrasound and its relationship to body weight, age and sex in normal subjects. J Clin Endocrinol Metab 56: 260–263
Czerny C, Hormann M, Kurtaran A, Niederle B (2003) Imaging of diseases of the thyroid gland in Austria. Wien Klin Wochenschr 115 [Suppl 2]: 71–74
Many MC, Denef JF, Haumont S (1984) Precocity of the endothelial proliferation during a course of rapid goitrogenesis. Acta Endocrinol 105: 487–491
Folkman J (1995) Seminars in medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med 333: 1757–1763
Vignola S, Picco P, Falcini F, Sabatini F, Buoncompagni A, Gattorno M (2002) Serum and synovial fluid concentration of vascular endothelial growth factor in juvenile idiopathic arthritides. Rheumatology (Oxford) 41: 691–696
Banks RE, Forbes MA, Kinsey SE, Stanley A, Ingham E, Walters C, et al (1998) Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. Br J Cancer 77: 956–964
Roberts WG, Palade GE (1995) Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J Cell Sci 108: 2369–2379
Nagura S, Katoh R, Miyagi E, Shibuya M, Kawaoi A (2001) Expression of vascular endothelial growth factor (VEGF) and VEGF receptor-1 (Flt-1) in Graves disease possibly correlated with increased vascular density. Human Pathology 32: 10–17
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hofmann, A., Gessl, A., Girschele, F. et al. Vascular endothelial growth factor in thyroid cyst fluids. Wien Klin Wochenschr 119, 248–253 (2007). https://doi.org/10.1007/s00508-006-0744-5
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s00508-006-0744-5